<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283983</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 097-13</org_study_id>
    <nct_id>NCT02283983</nct_id>
  </id_info>
  <brief_title>Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose</brief_title>
  <acronym>BANQUISE</acronym>
  <official_title>Evaluation of Cryoprotection of Nail Toxicity Induced by Docetaxel Low Cumulative Dose. Controlled, Randomized, Open, Multicentre Prospective.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the specific patient population studied receiving 5-Fluorouracil, epirubicin and&#xD;
      cyclophosphamide - Docetaxel sequence (cumulative dose &lt;300 mg / m2), using a cryoprotection&#xD;
      has never been assessed.&#xD;
&#xD;
      The effectiveness of cryoprotection of onycholysis secondary to Docetaxel is not well&#xD;
      established in this population (breast cancer in the adjuvant setting) and is based solely on&#xD;
      a publication (Scotté) that does not contain the same therapeutic modalities (dose&#xD;
      significantly higher). The few studies available have heterogeneous populations,&#xD;
      nonrandomized, retrospective or with a small sample.&#xD;
&#xD;
      By extension to what has been observed with higher cumulative doses of docetaxel, some teams&#xD;
      offer mittens and booties chilled to their patients, a practice that is not the subject of a&#xD;
      national consensus.&#xD;
&#xD;
      The investigators wish to accurately assess the effectiveness of mittens and slippers&#xD;
      chilled, their tolerance and their observance because of weak data on this specific&#xD;
      population in the literature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the occurrence of nail toxicity of grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 evaluated at 8 weeks post infusion of docetaxel.</measure>
    <time_frame>8 weeks post infusion of docetaxel</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Standard cryoprotection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proposal helmet without mittens and booties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cryoprotection with mittens and booties</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mittens and booties</intervention_name>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cooling helmet</intervention_name>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
    <arm_group_label>Standard cryoprotection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  upper age to 18 years&#xD;
&#xD;
          -  mammary adenocarcinoma nonmetastatic and histologically proven&#xD;
&#xD;
          -  wait under an adjuvant or neoadjuvant chemotherapy according to the following&#xD;
             conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100&#xD;
             (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500&#xD;
             or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3&#xD;
             cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++&#xD;
&#xD;
          -  Patient with the capacity/faculties to understand a newsletter and sign an informed&#xD;
             consent&#xD;
&#xD;
          -  Patient receiving social coverage&#xD;
&#xD;
          -  Patient who can be treated and followed in the center for a period of at least one&#xD;
             year&#xD;
&#xD;
          -  WHO scale 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  Diseases of the scalp or whatever hair-showing against helmet or alopecia&#xD;
&#xD;
          -  Using pre nail resin before and per chemotherapy&#xD;
&#xD;
          -  mammary adenocarcinoma stage IV&#xD;
&#xD;
          -  Indication of docetaxel for cancer of another organ than breast&#xD;
&#xD;
          -  Treatment processing or programmed during chemotherapy with an innovative molecule&#xD;
             being evaluated&#xD;
&#xD;
          -  Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.&#xD;
&#xD;
          -  Uncontrolled severe arterial disease.&#xD;
&#xD;
          -  Presence of a device&gt; grade 1 neuropathy before the start of chemotherapy&#xD;
&#xD;
          -  Patient unable to submit the protocol followed for psychological, social, family or&#xD;
             geographical&#xD;
&#xD;
          -  Patient with an incompatible underlying disease or concomitant with the inclusion in&#xD;
             the trial, whether psychiatric or somatic&#xD;
&#xD;
          -  Patient trust, guardianship, under legal protection measure, deprived of freedom&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Criteria for non randomization (before the first course of docetaxel) :&#xD;
&#xD;
               -  Presence of peripheral neuropathy&gt; grade 1 after the first 3 cycles of&#xD;
                  5-Fluorouracil, epirubicin and cyclophosphamide 100.&#xD;
&#xD;
               -  Presence of a nail or skin toxicity&gt; grade 1 after 3 cycles of 5-Fluorouracil,&#xD;
                  epirubicin and cyclophosphamide 100.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank PRIOU, PH</last_name>
    <role>Study Director</role>
    <affiliation>CHD Vendee La Roche sur Yon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - Nantes</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie Saint-Yves</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHBA Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

